Findings

What do systematic reviews say?

48 questions · 49 findings · 5 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 4.1%GRADE not reported 3 · 6.1%Very low 15 · 30.6%Low 17 · 34.7%Moderate 9 · 18.4%High 3 · 6.1%

Selective serotonin reuptake inhibitors vs MAOI

Leaving the study early · adults with panic disorder

SSRIs showed no clear difference in total number of dropouts compared with MAOIs (low certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 1 [0.07, 14.55]
1 study · 30 participants
Low

Selective serotonin reuptake inhibitors vs MAOI

Failure to remit at endpoint · adults with panic disorder

SSRIs showed no clear difference in failure to remit compared with MAOIs (moderate certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 0.93 [0.74, 1.17]
1 study · 366 participants
Moderate

Selective serotonin reuptake inhibitors vs MAOI

panic symptoms · adults with panic disorder

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs MAOI

Withdrawals due to adverse events · adults with panic disorder

SSRIs showed no clear difference in number of dropouts due to adverse events compared with MAOIs (low certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 1.26 [0.59, 2.7]
1 study · 366 participants
Low

Selective serotonin reuptake inhibitors vs SNRIs

Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder

SSRIs showed no clear difference in failure to respond compared with SNRIs (high certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 0.96 [0.75, 1.23]
2 studies · 991 participants
High

Selective serotonin reuptake inhibitors vs SNRIs

Leaving the study early · adults with panic disorder

SSRIs showed no clear difference in total number of dropouts compared with SNRIs (low certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 1.11 [0.74, 1.65]
2 studies · 991 participants
Low

Selective serotonin reuptake inhibitors vs SNRIs

Failure to remit at endpoint · adults with panic disorder

SSRIs showed no clear difference in failure to remit compared with SNRIs (high certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 1.05 [0.91, 1.21]
2 studies · 991 participants
High

Selective serotonin reuptake inhibitors vs SNRIs

panic symptoms · adults with panic disorder

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 945 participants
High

Selective serotonin reuptake inhibitors vs SNRIs

Withdrawals due to adverse events · adults with panic disorder

SSRIs showed no clear difference in number of dropouts due to adverse effects compared with SNRIs (low certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 1.86 [0.49, 7.05]
2 studies · 991 participants
Low

Selective serotonin reuptake inhibitors vs NaSSAs

Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs NaSSAs

Leaving the study early · adults with panic disorder

SSRIs showed no clear difference in total number of dropouts compared with naSSAs (low certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 1.5 [0.29, 7.73]
1 study · 30 participants
Low

Selective serotonin reuptake inhibitors vs NaSSAs

Failure to remit at endpoint · adults with panic disorder

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs NaSSAs

panic symptoms · adults with panic disorder

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Selective serotonin reuptake inhibitors vs NaSSAs

Withdrawals due to adverse events · adults with panic disorder

SSRIs showed no clear difference in number of dropouts due to adverse events compared with naSSAs (low certainty).

1 finding from 1 review

Antidepressants and benzodiazepines for panic disorder in adults 2016 · Cochrane Headline outcomes only
RR 1.5 [0.29, 7.73]
1 study · 30 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.94 [0.79, 1.11]
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.78 [0.52, 1.17]
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs atypical agent

Dropout · adults living with HIV and depression

Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in study dropouts at 6‐12 weeks compared with atypical agent (low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.67 [0.43, 6.45]
1 study · 70 participants
Low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Dropout · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 0.81 [0.51, 1.3]
2 studies · 64 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for depression in adults with HIV infection 2018 · Cochrane Headline outcomes only
RR 1.05 [0.67, 1.64]
1 study · 14 participants
Very low